inosine-pranobex and Uterine-Cervical-Neoplasms

Secondary prevention of cervical cancer is the identification and treatment of preinvasive forms of the disease, which include dysplasia or cervical intraepithelial neoplasia. Traditional surgical treatment of preinvasive neoplasia does not always result in elimination of the virus that, in its turn, cannot completely exclude the possibility of recurrence. The article presents references and own observations on possibilities of drug therapy in complex treatment for cervical neoplasia.

Topics: Adjuvants, Immunologic; Adult; Aged; Alphapapillomavirus; Anticarcinogenic Agents; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Inosine Pranobex; Middle Aged; Papillomavirus Infections; Treatment Outcome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms

We have studied the incidence, evolution and association with CIN of the cervico-vaginal infections by HPV. We noted over a period of time the diverse behaviour of "benign" and atypical alterations through colposcopic and cytohistological monitoring. We also noted the therapeutic efficacy in relation to the type of viral alterations and to the associated lesion (CIN). We emphasize the importance of accurate diagnosis, of aimed and personalized therapy and follow-up, in consideration of the natural history and of the evolutive potentiality of HPV infections.

Topics: Female; Humans; Inosine Pranobex; Neoplasm Recurrence, Local; Neoplasm Regression, Spontaneous; Papillomaviridae; Remission Induction; Tumor Virus Infections; Uterine Cervical Neoplasms; Vaginal Neoplasms

Inosiplex, a 3:1 molarcomplex of N, N-dimethylamino-2-propanol-p-acetamidobenzoate and inosine, which has been reported to exhibit antiviral activity in vitro and in vivo, enhanced cytotoxic effects of 5-fluorouracil (5-FU). Effects of inosiplex on the potentiation of cytotoxicity of 5-FU were investigated in vitro and in vivo. In vitro studies demonstrated that cytotoxic effects of 5-FU on cloning efficiency of HeLa cells were prominently enhanced by inosiplex, while inosiplex alone showed no cytotoxicity at the concentrations examined. Further, the survival time of mice intraperitoneally inoculated with Ehrlich ascites tumor cells was investigated. The mean survival time of mice treated with the combination of 5-FU and inosiplex significantly prolonged as compared with that of control animals or mice treated with inosiplex alone or 5-FU alone. Since inosiplex has been clinically studied as an antiviral agent and proved to be harmless to humans, the present results indicate that a combined administration of 5-FU and inosiplex may be effective in the treatment of human cancers.

Topics: Animals; Carcinoma, Ehrlich Tumor; Cell Division; Cell Survival; Drug Synergism; Female; Fluorouracil; HeLa Cells; Humans; Inosine; Inosine Pranobex; Mice; Uterine Cervical Neoplasms